MacroGenics grants Servier an option to license MGA271 for cancer; deal ends
MacroGenics Inc. (therapeutics for autoimmune and infectious diseases and cancer) has granted Servier SA an option to license exclusive worldwide rights (excluding the US, Canada, Mexico, Japan, Korea, and India) to MGA271, in Phase I for solid tumors.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.